Breaking News Instant updates and real-time market news.

CELG

Celgene

$102.17

-0.39 (-0.38%)

13:12
12/07/17
12/07
13:12
12/07/17
13:12

Celgene: ABRAXANE results show higher disease-free survival rate

The German Breast Group, or GBG, and Celgene announced long-term invasive disease-free survival results from the GeparSepto clinical trial comparing the investigational use of ABRAXANE to paclitaxel in early high-risk breast cancer patients at the 2017 San Antonio Breast Cancer Symposium. The results from the 1,206 patient study found that ABRAXANE demonstrated a significantly higher disease-free survival rate, a secondary efficacy endpoint, in high risk early breast cancer patients when compared to conventional solvent-based paclitaxel. In this large Phase III study, of which disease-free survival was a secondary endpoint, the investigational use of ABRAXANE was compared to conventional solvent-based paclitaxel followed by epirubicin/cyclophosphamide in both arms given all before surgery. The study found a significantly higher disease-free survival rate in patients receiving ABRAXANE compared to those receiving paclitaxel as part of a neoadjuvant treatment regimen. The rates of DFS were 87.1% vs. 80.7% at 3 years and 83.5% vs. 76.2% at 4 years, respectively. A treatment effect was observed in the predefined subset of patients with triple negative tumors and hormone receptor-positive, human epidermal growth factor receptor 2 negative tumors. Patients with triple negative breast cancer had DFS rates of 83.1% vs. 73.4% at 3 years, and 78.7% vs. 68.6% at 4 years. DFS was not significantly different in the TNBC subgroup. HR+/HER2- patients had DFS rates of 86.3% vs. 78.6% at 3 years and 80.8% vs. 72.8% at 4 years. Another secondary endpoint measure evaluated in the study was overall survival. No difference in OS was observed, however the OS findings are not yet mature. "These long-term findings show that weekly nab-paclitaxel followed by epirubicin/cyclophosphamide helped to significantly delay the progression of disease compared to solvent-based paclitaxel followed by epirubicin/cyclophosphamide in early high-risk breast cancer patients," stated Sibylle Loibl, Chair of GBG. "These findings are consistent with our previous findings and are very exciting, as they help us evaluate another potential treatment option for this high-risk patient group."

  • 10

    Dec

  • 18

    Jan

  • 25

    Mar

CELG Celgene
$102.17

-0.39 (-0.38%)

10/30/17
OPCO
10/30/17
NO CHANGE
Target $166
OPCO
Outperform
Oppenheimer raises Celgene target to $168 on 'highly positive' study
Oppenheimer analyst Leah Rush Cann raised her price 12- to 18-month price target for shares of Celgene (CELG) to $168 from $163 citing the "highly positive" Radiance trial results. The stock in midday trading is up 2% to $100.00. The study, evaluating the efficacy and safety of Ozanimod versus a first-line treatment, Biogen's (BIIB) Avonex, in patients with relapsing multiple sclerosis met primary and secondary endpoints with "highly positive and significant results," and serious adverse events were reported to be low and similar across all treatment arms, Cann tells investors in a research note. The analyst is now including "modest" estimated sales of Ozanimod in multiple sclerosis starting in 2019. She keeps an Outperform rating on Celgene.
11/01/17
CANT
11/01/17
NO CHANGE
Target $58
CANT
Neutral
Cantor ups bluebird target to $58, maintains Underweight rating
Cantor Fitzgerald analyst Elemer Piros raised his price target for bluebird bio (BLUE) to $58 from $39 following the introduction of multiple myeloma into his model. While no new data were introduced, partner Celgene (CELG) is planning to move the program to the pivotal setting, Piros tells investors in a research note. The analyst, however, remains "only cautiously optimistic" of the company's eventual success in sickle cell disease. The American Society of Hematology abstracts today provided an early glimpse at the modified drug manufacturing process for sickle cell disease, the analyst notes.
11/20/17
JEFF
11/20/17
NO CHANGE
Target $125
JEFF
Buy
Celgene shares can rebound to $125 in 12-18 months, says Jefferies
After hosting investor meetings with management, Jefferies analyst Michael Yee is more positive on his view that Celgene (CELG) shares can rebound to $125 over the next 12-18 months. The biotech closed Friday up 75c to $104.10. The company could generate "a conservative" $50B in free cash flow in the next five year even before Revlimid starts eroding in 2022, Yee tells investors in a research note. As such, management "can easily deploy the balance sheet" and bring in one or a few late-stage assets to diversify and ease investor concerns, the analyst adds. Yee thinks PARP inhibitors like Clovis Oncology (CLVS) "fit that mold and that's a good first step." The analyst has a Buy rating on Celgene with a $125 price target.
12/05/17
ADAM
12/05/17
INITIATION
Target $202
ADAM
Buy
bluebird bio initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated bluebird bio (BLUE) with a Buy rating citing its partnership with Celgene (CELG) and the long-term potential of bb2121, which could be used as an alternative or substitute for stem cell transplant in multiple myeloma. He also noted its improved process for its gene therapy product in addition to its drug pipeline. Newman has a $202 price target on bluebird bio shares.

TODAY'S FREE FLY STORIES

AEP

American Electric

$76.29

-0.22 (-0.29%)

17:28
12/14/17
12/14
17:28
12/14/17
17:28
Syndicate
Breaking Syndicate news story on American Electric »

American Electric files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$158.03

-6.62 (-4.02%)

17:25
12/14/17
12/14
17:25
12/14/17
17:25
Conference/Events
Sage Therapeutics management to meet with RBC Capital »

Dinner Meeting will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

ORCL

Oracle

$50.20

0.14 (0.28%)

17:24
12/14/17
12/14
17:24
12/14/17
17:24
Hot Stocks
Breaking Hot Stocks news story on Oracle »

Oracle CEO Hurd says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ADBE

Adobe

$175.00

-1.83 (-1.03%)

17:23
12/14/17
12/14
17:23
12/14/17
17:23
Hot Stocks
Adobe targeting subscription bookings growth of 20% in FY18 »

Says expect quarterly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ADBE

Adobe

$175.00

-1.83 (-1.03%)

17:20
12/14/17
12/14
17:20
12/14/17
17:20
Hot Stocks
Adobe says advertising cloud had a 'strong' year »

Says advertising cloud…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ORCL

Oracle

$50.19

0.14 (0.28%)

17:20
12/14/17
12/14
17:20
12/14/17
17:20
Hot Stocks
Breaking Hot Stocks news story on Oracle »

Oracle says currency…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ORCL

Oracle

$50.19

0.14 (0.28%)

17:19
12/14/17
12/14
17:19
12/14/17
17:19
Earnings
Oracle sees Q3 adjusted EPS 68c-70c, consensus 72c »

Sees Q3 revenue growth of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

UBA

Urstadt Biddle

$22.71

-0.48 (-2.07%)

, UBP

Urstadt Biddle Properties Inc.

$18.00

-0.01 (-0.06%)

17:17
12/14/17
12/14
17:17
12/14/17
17:17
Hot Stocks
Urstadt Biddle raises quarterly dividend by 0.5c to 27c »

At their regular meeting…

UBA

Urstadt Biddle

$22.71

-0.48 (-2.07%)

UBP

Urstadt Biddle Properties Inc.

$18.00

-0.01 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.19

0.14 (0.28%)

17:14
12/14/17
12/14
17:14
12/14/17
17:14
Hot Stocks
Oracle says customer adoption of cloud products 'remains very strong' »

Says expects to continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

NQ

NQ Mobile

$4.13

0.02 (0.49%)

17:14
12/14/17
12/14
17:14
12/14/17
17:14
Hot Stocks
NQ Mobile announces partnership with Chery Automotive »

NQ Mobile Inc announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

CVX

Chevron

$119.53

-0.4 (-0.33%)

, SLB

Schlumberger

$62.37

-0.93 (-1.47%)

17:12
12/14/17
12/14
17:12
12/14/17
17:12
Periodicals
Chevron near pact with Schlumberger to drill six Brazil wells, Reuters says »

Chevron (CVX) has reached…

CVX

Chevron

$119.53

-0.4 (-0.33%)

SLB

Schlumberger

$62.37

-0.93 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

VSTM

Verastem

$3.65

-0.15 (-3.95%)

17:07
12/14/17
12/14
17:07
12/14/17
17:07
Syndicate
Verastem files to sell $25M of common stock »

BTIG is acting as sole…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNR

Denbury Resources

$1.62

0.02 (1.25%)

17:06
12/14/17
12/14
17:06
12/14/17
17:06
Syndicate
Breaking Syndicate news story on Denbury Resources »

Denbury Resources files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCBS

Nicolet Bankshares

$56.52

-1.12 (-1.94%)

17:05
12/14/17
12/14
17:05
12/14/17
17:05
Initiation
Nicolet Bankshares initiated  »

Nicolet Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GALE

Galena

$0.32

0.0399 (14.24%)

17:05
12/14/17
12/14
17:05
12/14/17
17:05
Hot Stocks
Galena to adjourn special meeting until Friday, December 29 »

Galena Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDS

FactSet

$202.46

0.44 (0.22%)

17:04
12/14/17
12/14
17:04
12/14/17
17:04
Initiation
FactSet initiated  »

FactSet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

UTX

United Technologies

$123.76

-0.54 (-0.43%)

17:04
12/14/17
12/14
17:04
12/14/17
17:04
Hot Stocks
United Technologies awarded $6.7B U.S. Air Force contract »

United Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNPR

Juniper

$28.80

-0.31 (-1.06%)

17:03
12/14/17
12/14
17:03
12/14/17
17:03
Initiation
Juniper initiated  »

Juniper resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$37.90

-0.25 (-0.66%)

17:03
12/14/17
12/14
17:03
12/14/17
17:03
Initiation
Cisco initiated  »

Cisco resumed with a Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

ANET

Arista Networks

$226.72

1.59 (0.71%)

17:02
12/14/17
12/14
17:02
12/14/17
17:02
Initiation
Arista Networks initiated  »

Arista Networks resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

GRA

W.R. Grace

$69.98

-0.46 (-0.65%)

, ALB

Albemarle

$127.58

-2.2 (-1.70%)

17:01
12/14/17
12/14
17:01
12/14/17
17:01
Hot Stocks
W.R. Grace to acquire Polyolefin Catalysts unit of Albemarle for $416M »

W.R. Grace (GRA) signed…

GRA

W.R. Grace

$69.98

-0.46 (-0.65%)

ALB

Albemarle

$127.58

-2.2 (-1.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

LENS

Presbia

$1.93

-0.25 (-11.47%)

16:59
12/14/17
12/14
16:59
12/14/17
16:59
Hot Stocks
Presbia executive chairman resigns as company reorders operational priorities »

Presbia announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$42.67

-1.43 (-3.24%)

16:58
12/14/17
12/14
16:58
12/14/17
16:58
Periodicals
Elliot seeks ouster of Hess Corp. CEO, or sale of company, WSJ reports »

Elliott Management is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDR

DDR Corp.

$7.96

-0.11 (-1.36%)

16:52
12/14/17
12/14
16:52
12/14/17
16:52
Hot Stocks
Breaking Hot Stocks news story on DDR Corp. »

DDR Corp up 8.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDXC

ChromaDex

$6.24

-0.3 (-4.59%)

16:52
12/14/17
12/14
16:52
12/14/17
16:52
Syndicate
Breaking Syndicate news story on ChromaDex »

ChromaDex files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.